Revance Therapeutics, Inc. Annual Income Tax Expense (Benefit) in USD from 2016 to 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Summary
Revance Therapeutics, Inc. annual/quarterly Income Tax Expense (Benefit) history and growth rate from 2016 to 2023.
  • Revance Therapeutics, Inc. Income Tax Expense (Benefit) for the quarter ending September 30, 2023 was $300K, a 57.1% decline year-over-year.
  • Revance Therapeutics, Inc. annual Income Tax Expense (Benefit) for 2023 was $300K, a 57.1% decline from 2022.
  • Revance Therapeutics, Inc. annual Income Tax Expense (Benefit) for 2022 was $700K.
  • Revance Therapeutics, Inc. annual Income Tax Expense (Benefit) for 2021 was $0.000.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Annual (USD)
Income Tax Expense (Benefit), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 $300K -$400K -57.1% Jan 1, 2023 Dec 31, 2023 10-K 2024-02-28
2022 $700K +$700K Jan 1, 2022 Dec 31, 2022 10-K 2024-02-28
2021 $0 +$2.62M Jan 1, 2021 Dec 31, 2021 10-K 2024-02-28
2020 -$2.62M -$2.62M Jan 1, 2020 Dec 31, 2020 10-K 2023-02-28
2019 $0 -$3M -100% Jan 1, 2019 Dec 31, 2019 10-K 2022-02-28
2018 $3M +$3M Jan 1, 2018 Dec 31, 2018 10-K 2021-02-25
2017 $0 $0 Jan 1, 2017 Dec 31, 2017 10-K 2020-02-26
2016 $0 Jan 1, 2016 Dec 31, 2016 10-K 2019-02-28
* An asterisk sign (*) next to the value indicates that the value is likely invalid.